Search clinical trials for: AZD3839 Placebo

Total 53609 results

AstraZeneca

Completed

Multiple Ascending Doses (MAD) of AZD3199 Given Once Daily as Inhaled Formulation Via Turbuhaler to Healthy Men (AZD3199MAD)

Healthy Volunteers

Sweden
NSABP Foundation Inc
AstraZeneca

Completed

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Breast Neoplasms

United States
Sichuan University

Recruiting

CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma

Multiple Myeloma

China
AstraZeneca

Completed

Assess Safety, Tolerability and PK of AZD3199 in Japanese

Healthy

United Kingdom
Luca Ronfani
University of Trieste

Completed

Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

Urea Cycle Disorders, Inborn | Other Metabolic Diseases

Italy
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
SCRI Development Innovations, LLC
AstraZeneca

Completed

Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer

Lung Cancer
University of Chicago

Completed

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer

United States
AstraZeneca

Withdrawn

Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (IMAC/Herbst)

Non-Small-Cell Lung Carcinoma
Indiana University School of Medicine
AstraZeneca

Terminated

A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR (IUCRO-0021)

Refractory Germ Cell Tumors Expressing EGRF

United States
AstraZeneca

Completed

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Mesothelioma
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
Ege University

Completed

Care to Caregiver: The Effect of Reflexology on Sleep and Anxiety of Cancer Caregiver

Sleep | Anxiety

Turkey
AstraZeneca
Parexel

Completed

AZD3293 Thorough QT Study in Healthy Male Volunteers (AZD3293TQT)

Alzheimer's Disease

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
AstraZeneca

Completed

Trial of Iressa in Prostate Cancer Patients

Prostate Cancer

Canada
University Hospital of Crete

Completed

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Breast Cancer

Greece
AstraZeneca

Approved for marketing

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Non Small Cell Lung Cancer (NSCLC)

Taiwan, Thailand, Turkey, Brazil, Philippines, Russian Federation, Romania, Austria, Hungary, Bulgaria, Latvia, India, Argentina, Australia, Estonia, Malaysia, Mexico, Singapore, South Africa
AstraZeneca

Completed

Iressa Expanded Access Program (EAP)

Carcinoma | Neoplasm | Non-small-cell Lung | Metastases

United States
Assistance Publique - Hôpitaux de Paris
Iltoo Pharma

Completed

Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder (DEPIL-2)

Bipolar Depression

France
Orphan Australia

Completed

VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease

Crohn's Disease

Australia
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
M.D. Anderson Cancer Center
AstraZeneca

Completed

Iressa Study in Patients With Salivary Gland Cancer

Salivary Gland Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca

Completed

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Skin Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); AstraZeneca

Terminated

Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates

Lung Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
AstraZeneca

Completed

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma (NSCLC)

United States
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Esophageal Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck

Head and Neck Cancer

United States
AstraZeneca

Completed

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Advanced Tumor

Netherlands
Weill Medical College of Cornell University

Terminated

Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Chinese University of Hong Kong

Recruiting

RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19

COVID-19

Hong Kong
National University of Malaysia
Malaysia Palm Oil Board

Unknown

Supplementation of Oil Palm Phenolics to Healthy Participants (SPIRAL)

Cardiovascular Diseases | Hypercholesterolemia | Hyperlipidemias

Malaysia
Massachusetts General Hospital
National Cancer Institute (NCI); Dana-Farber Cancer Institute; AstraZeneca; Brigham...

Completed

Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

Head and Neck Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
University of South Carolina
U.S. Army Medical Research and Development Command

Completed

Dietary Seaweed and Early Breast Cancer: A Randomized Trial

Seaweed Associated Changes in Healthy Subjects

United States
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Active, not recruiting

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)

Critical Limb Ischemia

Poland
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)

Heart Failure

Poland
Gladwin, Mark, MD
National Institutes of Health (NIH); National Institute on Aging (NIA)

Completed

Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age (Nitrite)

Sedentary Lifestyle | Frailty | Aging

United States
Mersin University

Completed

The Effect of Post-Cesarean Section Acupressure on the Severity of Pain and First Mobilization Distance (Acupress)

Pain | Mobilization

Turkey
Hutchison Medipharma Limited
AstraZeneca

Completed

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Non-Small Cell Lung Cancer

China
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; AstraZeneca; Kentuckiana...

Completed

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Nonresectable Adrenocortical Carcinoma

United States
AstraZeneca

Active, not recruiting

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2)

Advanced ER-Positive HER2-Negative Breast Cancer

United States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Fengmei Lian
Guang'anmen Hospital of China Academy of Chinese Medical Sciences; Hubei Hospital... and other collaborators

Unknown

Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy

Type2 Diabetes | Diabetic Non-proliferative Retinopathy
AstraZeneca
Eli Lilly and Company

Completed

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy

United States
John Paul II Hospital, Krakow
National Center for Research and Development, Poland; KCRI

Completed

Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)

Myocardial Infarction

Poland

Search clinical trials for: AZD3839 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations